|
| Press Releases |
|
 |
|
| Tuesday, July 29, 2025 |
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. more info >> |
|
| Friday, July 25, 2025 |
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. more info >> |
|
| Wednesday, July 23, 2025 |
|
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand more info >> |
|
| Tuesday, July 22, 2025 |
|
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. more info >> |
|
| Wednesday, July 16, 2025 |
|
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA). more info >> |
|
| Monday, July 14, 2025 |
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dotinurad) in China as a treatment for Gout. more info >> |
|
| Tuesday, July 8, 2025 |
|
|
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that it has been selected for the highest rating of "Supplier Engagement Leader" in the Supplier Engagement Rating by the global environmental non-profit organization CDP. more info >> |
|
| Monday, June 2, 2025 |
|
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
| Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
| Wednesday, May 28, 2025 |
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
| Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Wednesday, May 21, 2025 |
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
RAK ICC Provides Strategic Solutions for Holding Companies and Regional Expansion
Jan 7, 2026 22:30 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Release "The TANAKA 2025" a Perfume that Expresses the Fragrance of Gold (Au)
Jan 7, 2026 22:00 JST
|
|
|
Toyota's European R&D center changes its name and competes in WEC with a new brand
Jan 7, 2026 21:50 JST
|
|
|
Military Metals Drills 23.2 Meters of 2.22% Antimony Including 7.9 Meters of 4.9% Antimony and 23.2 Meters of 1.27 g/t Gold Including 6.2 Meters of 3.17 g/t Gold at Flagship Trojarova Project
Jan 7, 2026 20:45 HKT/SGT
|
|
|
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries
Jan 7, 2026 12:27 JST
|
|
|
Fullerton Health Deepens Specialty Care Capabilities Through Acquisition of Singapore-Based Otolaryngology Practice, The ENT Clinic
Jan 7, 2026 10:30 HKT/SGT
|
|
|
Radisson Announces Additional High-Grade Drill Results and Further Extends New Mineralization Beneath the Historic O'Brien Gold Mine
Jan 6, 2026 20:00 HKT/SGT
|
|
|
Hong Kong Toys & Games Fair leads market innovation, debut 'Pop & Play' pavilion opens to industry and public
Jan 6, 2026 18:50 HKT/SGT
|
|
|
CTF Life Amplifies Ecosystem Synergy
Jan 6, 2026 15:35 HKT/SGT
|
|
|
Mitsubishi Motors to Celebrate "Delica Festival" with Custom Versions of Delica D:5 and Delica Mini at Tokyo Auto Salon 2026
Jan 6, 2026 16:25 JST
|
|
|
Mitsubishi Motors Launches the Xforce in Taiwan
Jan 6, 2026 14:42 JST
|
|
|
">
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Jan 6, 2026 10:43 JST
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026 
Jan 6, 2026 04:41 HKT/SGT
|
|
|
Notice on the Establishment of a Special Subsidiary
Jan 5, 2026 21:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Jan 5, 2026 21:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
